Tempus AI will soon launch xH, its first whole-genome sequencing (WGS) assay for clinical use. The test identifies actionable cancer targets in blood and bone marrow samples. It specifically targets hematologic malignancies, including leukemia and myelodysplastic syndromes.
The xH assay replaces multiple diagnostic tests with a single workflow. This consolidation provides a comprehensive genomic profile to help physicians determine precise treatments faster.
Data from the 2026 ASCO Annual Meeting showed the assay uncovered 40% more clinically relevant findings than traditional methods. Tempus AI expects to accept commercial clinical orders for the test later this year.